Published in Oncogene on February 01, 1994
Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A (1996) 3.56
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nat Rev Genet (2010) 1.82
Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol (2007) 1.77
Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol (2002) 1.41
Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer (2006) 1.37
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.32
RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res (2008) 1.30
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res (2009) 1.29
Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol (2001) 1.29
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res (2008) 1.27
DNA copy number changes in thyroid carcinoma. Am J Pathol (1999) 1.09
MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther (2010) 1.08
Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol (2002) 1.08
Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol (2009) 1.06
Translocations in epithelial cancers. Biochim Biophys Acta (2009) 1.04
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) (2012) 1.00
Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line. Mol Cancer (2010) 0.97
Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. Mol Cell Biol (1998) 0.96
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol (2002) 0.95
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
A new mechanism of BRAF activation in human thyroid papillary carcinomas. J Clin Invest (2005) 0.93
New targeted therapies for thyroid cancer. Curr Genomics (2011) 0.93
Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer (2014) 0.93
RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer (2014) 0.92
What is New on Thyroid Cancer Biomarkers. Biomark Insights (2008) 0.91
Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med (2013) 0.89
Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts. Hum Genet (2012) 0.88
Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis. Thyroid Res (2011) 0.87
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget (2015) 0.86
Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics (2011) 0.86
Gene position within chromosome territories correlates with their involvement in distinct rearrangement types in thyroid cancer cells. Genes Chromosomes Cancer (2009) 0.86
Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Br J Cancer (2001) 0.85
Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol (2013) 0.85
Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front Endocrinol (Lausanne) (2012) 0.83
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol (2016) 0.83
BAC-FISH assays delineate complex chromosomal rearrangements in a case of post-Chernobyl childhood thyroid cancer. Folia Histochem Cytobiol (2009) 0.82
RET/PTC rearrangements arising from a small population of papillary thyroid carcinoma cells, possible candidate for passenger mutation. Virchows Arch (2009) 0.82
New treatment in advanced thyroid cancer. J Oncol (2012) 0.81
Frequency of close positioning of chromosomal loci detected by FRET correlates with their participation in carcinogenic rearrangements in human cells. Genes Chromosomes Cancer (2012) 0.80
Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity. Cell Mol Life Sci (2012) 0.79
Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas. Br J Cancer (2003) 0.79
Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations. PLoS One (2014) 0.79
Central role of RET in thyroid cancer. Cold Spring Harb Perspect Biol (2013) 0.79
RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival-nested material. Br J Cancer (1996) 0.79
Expression of Ret/PTC1, -2, -3, -delta3 and -4 in German papillary thyroid carcinoma. Br J Cancer (1998) 0.78
Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma. PLoS One (2014) 0.78
Mouse models of endocrine tumours. Best Pract Res Clin Endocrinol Metab (2010) 0.78
Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res (2011) 0.77
Sympathoadrenal hyperplasia causes renal malformations in Ret(MEN2B)-transgenic mice. Am J Pathol (1999) 0.77
Thyroid Cancer: Role of RET and Beyond. Eur Thyroid J (2012) 0.76
B-Raf mutation and papillary thyroid carcinoma patients. Oncol Lett (2016) 0.76
Mouse models of follicular and papillary thyroid cancer progression. Front Endocrinol (Lausanne) (2012) 0.76
Nicotine-induced protein expression profiling reveals mutually altered proteins across four human cell lines. Proteomics (2016) 0.76
The RET proto-oncogene: a challenge to our understanding of disease pathogenesis. Pediatr Surg Int (1997) 0.75
Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther (2015) 0.75
Identification of the RNA binding segment of human U1 A protein and definition of its binding site on U1 snRNA. EMBO J (1989) 4.69
Major determinants of the specificity of interaction between small nuclear ribonucleoproteins U1A and U2B'' and their cognate RNAs. Nature (1990) 4.67
MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer (2006) 4.11
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene (2007) 3.29
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science (1984) 2.97
Changing the RNA polymerase specificity of U snRNA gene promoters. Cell (1988) 2.85
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (1995) 2.83
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res (1999) 2.56
Diversity in the signals required for nuclear accumulation of U snRNPs and variety in the pathways of nuclear transport. J Cell Biol (1991) 2.45
Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol (1999) 2.38
The FHIT gene 3p14.2 is abnormal in lung cancer. Cell (1996) 2.36
Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A (1997) 2.36
Functional analysis of mutant Xenopus U2 snRNAs. Cell (1989) 2.23
Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol (1995) 2.22
Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope (1997) 2.15
High level expression of the HMGI (Y) gene during embryonic development. Oncogene (1996) 2.13
The U2B'' RNP motif as a site of protein-protein interaction. EMBO J (1990) 2.12
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol (1999) 2.11
Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol Cell Biol (1993) 2.08
Role of the high mobility group A proteins in human lipomas. Carcinogenesis (2001) 2.08
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res (1998) 2.00
Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res (1998) 1.96
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
Central-nervous-system toxoplasmosis in homosexual men and parenteral drug abusers. Ann Intern Med (1984) 1.88
Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer (2002) 1.87
Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev (2001) 1.85
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res (1996) 1.85
Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 1.76
bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood (1992) 1.69
The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet (2001) 1.67
One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol (1987) 1.66
The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene (1995) 1.61
Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. Exp Cell Res (1989) 1.61
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc Natl Acad Sci U S A (2001) 1.60
Multiple domains of U1 snRNA, including U1 specific protein binding sites, are required for splicing. EMBO J (1990) 1.60
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest (1993) 1.57
Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene (1997) 1.57
TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene (1992) 1.55
Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene (2006) 1.55
p53 activity and chemotherapy. Nat Med (1996) 1.53
Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene (1998) 1.52
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest (1992) 1.52
The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene (1990) 1.52
Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene (1992) 1.51
Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J (1997) 1.51
Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res (1992) 1.50
Aberrant forms of bacteria and fungi found in blood or cerebrospinal fluid. Arch Intern Med (1969) 1.49
Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A (2000) 1.47
The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A (1999) 1.47
Structural features and selective expression of three Ly-5+ cell-surface molecules. Immunogenetics (1981) 1.47
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A (1992) 1.46
CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro. Blood (1993) 1.44
Immunological studies on viral polypeptide synthesis in cells replicating murine sarcoma-leukemia virus. J Virol (1972) 1.44
Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene (1996) 1.39
Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res (1997) 1.39
The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol (1995) 1.38
Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res (1996) 1.37
High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab (1999) 1.37
Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res (1995) 1.33
Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet (1995) 1.33
A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene (2000) 1.33
Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol (2009) 1.33
Evidence that a salt bridge in the light chain contributes to the physical stability difference between heavy and light human ferritins. J Biol Chem (1992) 1.30